Matches in Wikidata for { <http://www.wikidata.org/entity/Q97529057> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q97529057 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q97529057 description "im Juni 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q97529057 description "scientific article published on 01 June 2020" @default.
- Q97529057 description "wetenschappelijk artikel" @default.
- Q97529057 description "наукова стаття, опублікована 1 червня 2020" @default.
- Q97529057 name "Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo"" @default.
- Q97529057 name "Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo"" @default.
- Q97529057 type Item @default.
- Q97529057 label "Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo"" @default.
- Q97529057 label "Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo"" @default.
- Q97529057 prefLabel "Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo"" @default.
- Q97529057 prefLabel "Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo"" @default.
- Q97529057 P1433 Q97529057-AF8362CF-9D73-4063-BB12-E5ACD966D759 @default.
- Q97529057 P1476 Q97529057-1DF3B603-1097-4C90-8C48-4AD8E666BB22 @default.
- Q97529057 P2093 Q97529057-4A9AB737-92D5-42D0-A530-39B6219E17A0 @default.
- Q97529057 P2093 Q97529057-8A1770B4-BA09-44A3-B6FE-2EF5F446693C @default.
- Q97529057 P2093 Q97529057-D387FAC6-2DC6-4346-B0F3-9FEEB54BB41D @default.
- Q97529057 P2093 Q97529057-E3D1E907-05AE-4D91-82A3-375B16C11FA0 @default.
- Q97529057 P304 Q97529057-7B3CA6CC-B5C0-43AC-B9E2-46185B1A15AA @default.
- Q97529057 P31 Q97529057-E541CF99-83D9-4A12-B273-6C58629D9B44 @default.
- Q97529057 P356 Q97529057-23657EAE-AF3E-4AF8-99F6-347C221E0AD1 @default.
- Q97529057 P433 Q97529057-B5D72DE6-50E1-467C-A382-22498C6843CF @default.
- Q97529057 P478 Q97529057-F6761680-3616-4A16-A308-30B192F0850E @default.
- Q97529057 P577 Q97529057-34821E5C-8885-45E8-A80A-1612F38532A3 @default.
- Q97529057 P698 Q97529057-20B0F7AA-A206-458D-AD13-1E89900655BA @default.
- Q97529057 P356 TAU-2020-02 @default.
- Q97529057 P698 32676385 @default.
- Q97529057 P1433 Q27724139 @default.
- Q97529057 P1476 "Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo"" @default.
- Q97529057 P2093 "Kanya Kaga" @default.
- Q97529057 P2093 "Miki Fuse" @default.
- Q97529057 P2093 "Tomohiko Kamasasko" @default.
- Q97529057 P2093 "Tomonori Yamanishi" @default.
- Q97529057 P304 "1009-1012" @default.
- Q97529057 P31 Q13442814 @default.
- Q97529057 P356 "10.21037/TAU-2020-02" @default.
- Q97529057 P433 "3" @default.
- Q97529057 P478 "9" @default.
- Q97529057 P577 "2020-06-01T00:00:00Z" @default.
- Q97529057 P698 "32676385" @default.